GenFleet Therapeutics (HKG:2595) said GFH375 entered a phase II study for first-line treatment of patients with non-small cell lung cancer.
The trial will be conducted in a number of clinical sites across China, with Guangdong Provincial People's Hospital as the leading site, according to a Wednesday Hong Kong bourse filing.